Navigation Links
MIT: Making waves in the brain
Date:4/26/2009

CAMBRIDGE, Mass.--Scientists have studied high-frequency brain waves, known as gamma oscillations, for more than 50 years, believing them crucial to consciousness, attention, learning and memory. Now, for the first time, MIT researchers and colleagues have found a way to induce these waves by shining laser light directly onto the brains of mice.

The work takes advantage of a newly developed technology known as optogenetics, which combines genetic engineering with light to manipulate the activity of individual nerve cells. The research helps explain how the brain produces gamma waves and provides new evidence of the role they play in regulating brain functions insights that could someday lead to new treatments for a range of brain-related disorders.

"Gamma waves are known to be [disrupted] in people with schizophrenia and other psychiatric and neurological diseases," says Li-Huei Tsai, Picower Professor of Neuroscience and a Howard Hughes Medical Institute investigator. "This new tool will give us a great chance to probe the function of these circuits."

Tsai co-authored a paper about the work that appears in the April 26 online issue of Nature.

Gamma oscillations reflect the synchronous activity of large interconnected networks of neurons, firing together at frequencies ranging from 20 to 80 cycles per second. "These oscillations are thought to be controlled by a specific class of inhibitory cells known as fast-spiking interneurons," says Jessica Cardin, co-lead author on the study and a postdoctoral fellow at MIT's McGovern Institute for Brain Research. "But until now, a direct test of this idea was not possible."

To determine which neurons are responsible for driving the oscillations, the researchers used a protein called channelrhodopsin-2 (ChR2), which can sensitize neurons to light. "By combining several genetic tricks, we were able to express ChR2 in different classes of neurons, allowing us to manipulate their
'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Making a point: Picoscale stability in a room-temperature AFM
2. It takes a genome: How a clash between our genes and modern life is making us sick
3. MacArthur Foundation awards planning grant to improve decision-making in energy policy
4. U of Minnesota research finds most road salt is making it into the states lakes and rivers
5. Process can cut the cost of making cellulosic biofuels
6. How chromosomes meet in the dark -- Switch that turns on X chromosome matchmaking
7. Tips for making a green holiday from the worlds largest scientific society
8. Making the ultimate family sacrifice
9. Scientists present moving theory behind bacterial decision-making
10. Making flies sick reveals new role for growth factors in immunity
11. Making metabolism more inefficient can reduce obesity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...erican adolescents exposed to cigarette smoking sc...t themselves, and this may be part of the accultur...according to new study findings. , "Our study su...s and highlights the global implementation of the ...Tobacco Control, which includes guidelines for cou...
(Date:12/2/2009)...versity of Georgia College of Veterinary Medicine ...d open new avenues for treating Ichthyophthirius m...protozoan parasite that commonly attacks freshwate...g, researchers found that Ich harbors two apparent... which are usually found free-living, and Ricketts...
(Date:12/2/2009)... Foundation is pleased to announce the 2009 winner..., A. N. Pritzker Distinguished Service Professor E...and Molecular Biology, The University of Chicago, ...memorate the 15th anniversary of the Manpei Suzuki...ghtened researchers in the field of diabetes aroun...
Breaking Biology News(10 mins):Watching movies featuring characters who smoke negatively influences Mexican-American teens 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program 3 p m Tuesday October 27 14442 1Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program 3 p m Tuesday October 27 14442 2The Governator and the Disintegrator 3A A Sharp Match Holding Pharmaceutical Companies Accountable 5416 1The Governator and the Disintegrator 3A A Sharp Match Holding Pharmaceutical Companies Accountable 5416 2The Governator and the Disintegrator 3A A Sharp Match Holding Pharmaceutical Companies Accountable 5416 3ATS Medical Announces Receipt of CE Mark for the New ATS CryoMaze 10 S Probe 5414 1ATS Medical Announces Receipt of CE Mark for the New ATS CryoMaze 10 S Probe 5414 2ATS Medical Announces Receipt of CE Mark for the New ATS CryoMaze 10 S Probe 5414 3ATS Medical Announces Receipt of CE Mark for the New ATS CryoMaze 10 S Probe 5414 4
..., Germany,s Federal Minister for Food, Agricultur... the cultivation of genetically modified maize. Th...ister noted that the ban is an isolated decision o...f green genetic engineering. Europe,s highest lice...d no reservations about the cultivation of genetic...
..., NEW ORLEANSAmyotrophic lateral sclerosis (ALS) ... brain and spinal cord. The disease causes progres...h within five years of symptoms. Although ALS (Lou...go, neither the cause nor a cure have been found, ...development, including oxidative stress. , Coffe...
..., NEW ORLEANSThe connection between the body, min...scientific inquiry for some 20 years. The notion t...a role in maintaining health and preventing diseas...es of a layman, Norman Cousins. In the 1970s, Cous...lar Saturday Review, was diagnosed with an autoimm...
Other Biology News:Joint statement by German science organizations on green genetic engineering 2Caffeine appears to be beneficial in males -- but not females -- with Lou Gehrig's disease 2Caffeine appears to be beneficial in males -- but not females -- with Lou Gehrig's disease 3Laughter remains good medicine 2Laughter remains good medicine 3
(Date:12/2/2009)... Peregrine Pharmaceutica...n of patient enrollment in a dose confirmation and...relapsed glioblastoma multiforme (GBM), the deadli...noclonal antibody linked to a radioisotope being d...tara specifically targets cells at the center of b...
(Date:12/2/2009)...lands, December 2 Pepscan Holding ...cusing on protein mimicking,technology for the gen...t it,has appointed Wim E.M. Mol, Ph.D. as new Chie...sponsible for all of Pepscans corporate functions ... of the company. He brings to,Pepscan more than 20...
(Date:12/2/2009)...PRNewswire/ -- S*BIO Pte Ltd today announced data ...1518, at The American Society of Hematology 51st A... Data will be presented on the clinical results fr...ailing its safety, tolerability and pharmacokineti...anging from 100 to 600 mg. These doses were admini...
(Date:12/2/2009)...wswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ:...armaceutical company focused on endocrine therapy ...nd Drug Administration (FDA) has granted Fast Trac...nhibitor compound, perifosine (KRX-0401), for the ... Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX),...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...pherix Incorporated (Nasdaq: SPEX ), an innovato...vider of technical and regulatory consulting servi...eutical companies, today announced that on April 2...DAQ that the Company was not currently in complian...ix fell out of compliance following the death of t...
...no Corporation (Nasdaq: VOLC ), a leader in the ...or the diagnosis and treatment of coronary and per...ll report its operating results for the first quar...pany will hold a conference call to discuss its fi...ll interested parties at 2 p.m., Pacific Daylight ...
...ril 27 Cellectricon, a leading,provider of automa...announced,its collaboration with BioFocus DPI, a c...se in ion channel screening. BioFocus DPI will uti...ed patch clamp (APC) system, to,further increase i...ticularly,for fast ligand-gated ion channels. , ...
Other Biology Technology:Spherix Recruiting New 'Independent' Director to Regain NASDAQ Compliance 2Spherix Recruiting New 'Independent' Director to Regain NASDAQ Compliance 3Volcano Corporation Schedules First Quarter Conference Call, Webcast 2Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery 2
RNA oligos ready-to-use from Thermo Scientific
iEMS Incubator/Shaker HT 1 module (100-214 V) from Thermo Scientific
...ap analog in which the 3 OH group (closer to m7G) ...n, the RNA polymerase can only initiate transcript... ARCA incorporation in the forward orientation. As...ventional cap analog, 100% of the transcripts synt...
G(5)ppp(5)G from Ambion
Biology Products: